Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia

被引:92
|
作者
Ryan, Michael B. [1 ,2 ,3 ]
Bair-Marshall, Chloe [4 ]
Nelson, Alexandra B. [1 ,2 ,3 ,4 ]
机构
[1] UCSF, Neurosci Grad Program, San Francisco, CA 94158 USA
[2] UCSF, Weill Inst Neurosci, San Francisco, CA 94158 USA
[3] UCSF, Kavli Inst Fundamental Neurosci, San Francisco, CA 94158 USA
[4] UCSF, Dept Neurol, San Francisco, CA 94158 USA
来源
CELL REPORTS | 2018年 / 23卷 / 12期
关键词
DOPA-INDUCED DYSKINESIA; MEDIUM SPINY NEURONS; PROJECTION NEURONS; SUBTHALAMIC NUCLEUS; CRE-RECOMBINASE; DISEASE; ACTIVATION; APOMORPHINE; RECORDINGS; PLASTICITY;
D O I
10.1016/j.celrep.2018.05.059
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Action selection relies on the coordinated activity of striatel direct and indirect pathway medium spiny neurons (dMSNs and iMSNs, respectively). Loss of dopamine in Parkinson's disease is thought to disrupt this balance. While dopamine replacement with levodopa may restore normal function, the development of involuntary movements (levodopa-induced dyskinesia [LID]) limits therapy. How chronic dopamine loss and replacement with levodopa modulate the firing of identified MSNs in behaving animals is unknown. Using optogenetically labeled striatel single-unit recordings, we assess circuit dysfunction in parkinsonism and LID. Counter to current models, we found that following dopamine depletion, iMSN firing was elevated only during periods of immobility, while dMSN firing was dramatically and persistently reduced. Most notably, we identified a subpopulation of dMSNs with abnormally high levodopa-evoked firing rates, which correlated specifically with dyskinesia. These findings provide key insights into the circuit mechanisms underlying parkinsonism and LID, with implications for developing targeted therapies.
引用
收藏
页码:3438 / +
页数:14
相关论文
共 50 条
  • [31] Emerging drugs for levodopa-induced dyskinesia
    Al Dakheel, Amaal
    Beaulieu-Boire, Isabelle
    Fox, Susan H.
    EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (03) : 415 - 429
  • [32] Noradrenergic drugs for levodopa-induced dyskinesia
    Colosimo, C
    Craus, A
    CLINICAL NEUROPHARMACOLOGY, 2003, 26 (06) : 299 - 305
  • [33] Clinical pharmacology of levodopa-induced dyskinesia
    Nutt, JG
    ANNALS OF NEUROLOGY, 2000, 47 (04) : S160 - S166
  • [34] Striatal histone post-translational modifications in animal models of levodopa-induced dyskinesia
    Nicholas, A. P.
    Lubin, F. D.
    Hallett, P. J.
    Vattem, P.
    Ravenscroft, P.
    Bezard, E.
    Zhou, S.
    Fox, S. H.
    Brotchie, J. M.
    Sweatt, J. D.
    Standaert, D. G.
    MOVEMENT DISORDERS, 2008, 23 (01) : S82 - S82
  • [35] Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study
    Brumberg, Joachim
    Kuesters, Sebastian
    Al-Momani, Ehab
    Marotta, Giorgio
    Cosgrove, Kelly P.
    van Dyck, Christopher H.
    Herrmann, Ken
    Homola, Gyoergy A.
    Pezzoli, Gianni
    Buck, Andreas K.
    Volkmann, Jens
    Samnick, Samuel
    Isaias, Ioannis U.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (09): : 632 - 639
  • [36] THE USE OF THALAMOTOMY IN THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA
    PAGE, RD
    ACTA NEUROCHIRURGICA, 1992, 114 (3-4) : 77 - 117
  • [38] SODIUM VALPROATE IN TREATMENT OF LEVODOPA-INDUCED DYSKINESIA
    PRICE, PA
    PARKES, JD
    MARSDEN, CD
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1978, 41 (08): : 702 - 706
  • [39] A role for serotonergic neurons in levodopa-induced dyskinesia
    Alex Chase
    Nature Reviews Neurology, 2014, 10 (4) : 180 - 180
  • [40] Levodopa-induced dyskinesia in Parkinson's disease
    Brotchie, JM
    Lee, J
    Venderova, K
    JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (03) : 359 - 391